Abstract
To determine effectiveness and safety of colchicine in Peyronie's disease. In all, 84 patients with Peyronie's disease who did not have calcified plaque were entered into study. The mean disease duration was 15 months. A medical history was obtained, and physical examination, penile X-ray, and dynamic penile duplex ultrasound were performed. Patients were randomly divided into group 1, those who received 0.5–2.5 mg colchicine daily for 4 months and group 2, who received placebo for the same period. Response to therapy was assessed objectively, during dynamic penile duplex ultrasound, as well as subjectively using International Index of Erectile Function (IIEF) questionnaire and measurements of pain, duration of disease, penile curvature, and plaque size. Differences before and after treatment and among the three Kelami classification groups were assessed. In total, 78 (92.8%) completed the whole treatment schedule. Pain resolved in 60 and 63.6% of the patients treated with colchicine and placebo, respectively (P>0.05). After therapy, in subjects and controls a reduction in the penile deformity was observed by 17.1 and 18.4% of the patients (P>0.05), and a decrease in plaque size was noticed by 10.5 and 10%, respectively (P>0.05). Objective measurements did not demonstrate any difference in plaque size or penile curvature. There were no substantial differences in response to treatment based on duration of disease or within the three Kelami classification groups. Significant drug-related adverse effects occurred in colchicine group and in two cases was treatment discontinued. Colchicine is no better than placebo in improvement of pain, curvature angle, or plaque size in patients with Peyronie's disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Levine LA . Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997; 158: 1395–1401.
Carson CC . Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective? Tech Urol 1997; 3: 135–140.
Gelbard MK, Dorey F, James K . The natural history of Peyronie's disease. J Urol 1990; 144: 1376–1381.
Ralph DJ, Brooks MD, Bottazzo GF, Pyror JP . The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 648–653.
Morgan RJ, Pryor JP . Procarbazine (Natulan) in the treatment of Peyronie's disease. Br J Urol 1978; 50: 111–116.
Akkus E et al. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 291–296.
Winter CC, Khanna R . Peyronie's disease: results with dermo-jet injection of dexamethasone. J Urol 1975; 114: 898–903.
Gelbard MK, James K, Riach P, Dorey F . Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol 1993; 149: 56–60.
Morales A, Bruce AW . The treatment of Peyronie's disease with parathyroid hormone. J Urol 1975; 114: 901–906.
Bartsch G, Menander-Huber KB, Marberger H . Orgotein, a new drug for the treatment of Peyronie's disease. Eur J Rheumatol Inflamm 1981; 4: 250–255.
Duncan MR, Berman B, Nseyo UO . Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblast by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 89–94.
Incrocci L, Hop W, Slob A . Current sexual functioning in 106 patients with Peyronie's disease treated with radiotherapy 9 years earlier. Urology 2000; 56: 1030–1033.
Hauck E et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. Eur Urol 2000; 38: 663–670.
Frank IN, Scott WW . The ultrasonic treatment of Peyronie's disease. J Urol 1971; 106: 83–88.
El-Sakka AI et al. The effect of surgical trauma on rat tunica albuginea. J Urol 1998; 159: 1700–1706.
Diegelmann RF, Peterkofsky B . Inhibition of collagen secretion from bone and cultured fibroblast by microtubular disruptive drugs. Proc Natl Acad Sci USA 1972; 69: 892–898.
Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of Erectile dysfunction. Urology 1997; 49: 620–625.
Kelami A . Classification of congenital and acquired penile deviation. Urol Int 1983; 38: 822–826.
Steward S, Malto M, Sandberg L, Colburn KK . Increase serum level of anti-elastin antibodies in patients with Peyronie's disease. J Urol 1994; 152: 105–111.
Somers KD et al. Isolation and characterization of collagen in Peyronie's disease. J Urol 1989; 141: 629–634.
Border WA, Ruoslahti E . Transforming growth factor beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1–7.
Taylor AC . The mechanism of colchicine inhibition of mitosis. I. Kinetics of inhibition and the binding of H3-colchicine. J Cell Biol 1965; 25: 145–150.
Tilney LG, Hiramoto Y, Marsland D . Studies on the microtubules in heliozoa. J Cell Biol 1966; 29: 77–82.
Ehrilich HP, Bornstein P . Microtubules in transcellular movement of procollagen. Nature (New Biol) 1972; 238: 257–261.
El-Sakka AI et al. The effects of colchicine on a Peyronie's-like condition in an animal model. J Urol 1999; 161: 1980–1983.
Kadioglu A et al. Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169–175.
Claudio T et al. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 2003–2008.
Levine LA, Goldman KE, Greenfield JM . Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol 2002; 168: 621–626.
Husain J et al. Extracorporeal shockwave therapy in the management of Peyronie's disease. Br J Urol 2000; 68: 466–468.
Williams J, Thomas GG . The natural history of Peyronie's disease. J Urol 1970; 73: 75–79.
Kadioglu A . Lessons learned from 307 men with Peyronie's disease. J Urol Suppl 2001; 165: 202, abstract 838.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Safarinejad, M. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 16, 238–243 (2004). https://doi.org/10.1038/sj.ijir.3901185
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901185
Keywords
This article is cited by
-
A systematic review of non-surgical management in Peyronieʼs disease
International Journal of Impotence Research (2023)
-
Trends in treatment of Peyronie’s disease in adult men in the United States from 2008 to 2017—results from an encounter and claims database
International Journal of Impotence Research (2022)
-
Nonsurgical management of Peyronie’s disease
Nature Reviews Urology (2019)
-
Contemporary Review of Peyronie’s Disease Treatment
Current Urology Reports (2018)
-
Aktuelle Therapie der Induratio penis plastica (IPP)
Der Urologe (2018)